One Obesity PPG Meeting Minutes

Date: 20 May 2025
Chair: Thomas Turpin-Jelfs (TCIT)
Attendees: Chris, Itai, Maria, Lisa, Nina, Timothy, Inger, others joined via chat.
Apologies: Not stated
Location: Virtual/Online

 ---

Executive Summary

ProposalPPG DecisionAssessment of the Carbon Emissions Impact Associated with Semaglutide for Obesity/Diabetes in the UK✅ EndorsedIndirect Treatment Comparison (ITC) of Oral semaglutide 25mg with s.c. injectable semaglutide 2.4mg✅ EndorsedRelationships between body mass indices and surgical replacements of knee and hip joints✅ EndorsedImpact of Wegovy on household shopping, lifestyle and behavioural metrics in US; Impact of Wegovy on food noise and mental wellbeing in US❌ Not endorsed (pending further clarification)Real world cardiovascular and gastro-intestinal benefit of Wegovy compared to Zepbound in US⚠️ Deferred (pending data analysis)

 ---

Proposal Summaries

Assessment of the Carbon Emissions Impact Associated with Semaglutide for Obesity/Diabetes in the UK

Presenter(s): CJLU
Source: Slide-sourced

Who / What / Actions

WhoWhatActionsCJLUPresented assessment of carbon emissions impactNone statedAllReview / decisionNot stated

Abstract / Manuscript
Target congress / journal: Value in Health / Pharmacoeconomics
Submission date / deadline: Q3 2025

Presentation Summary
Aim / Objective: Evaluate carbon emissions impact of Semaglutide
Design / Data sources: Utilized established trials and health economic models
Key findings / conclusions: Net reduction in greenhouse gas emissions

Questions and Comments
[H] asked about target audience and comparison with other drugs.
[D] replied focus on public payers and no current comparable data.

Decision: ✅ Endorsed (Slide-sourced)

 ---

Indirect Treatment Comparison (ITC) of Oral semaglutide 25mg with s.c. injectable semaglutide 2.4mg

Presenter(s): ICSM
Source: Slide-sourced

Who / What / Actions

WhoWhatActionsICSMPresented indirect treatment comparisonNone statedAllReview / decisionNot stated

Abstract / Manuscript
Target congress / journal: Obesity Week / Journal of Medical Decision Making
Submission date / deadline: 2 July 2025

Presentation Summary
Aim / Objective: Compare efficacy of oral vs subcutaneous semaglutide
Design / Data sources: OASIS-4 and STEP 1 trials
Key findings / conclusions: Equivalence in efficacy demonstrated

Questions and Comments
[H] suggested additional modeling for exposure.
[I] agreed to consider inclusion of modeling data.

Decision: ✅ Endorsed (Slide-sourced)

 ---

Relationships between body mass indices and surgical replacements of knee and hip joints

Presenter(s): TMYU
Source: Slide-sourced

Who / What / Actions

WhoWhatActionsTMYUPresented correlation between BMI and joint replacementNone statedAllReview / decisionNot stated

Abstract / Manuscript
Target congress / journal: Obesity Week 2025
Submission date / deadline: July 2025

Presentation Summary
Aim / Objective: Investigate association between obesity and surgeries
Design / Data sources: Retrospective study using AEMR PPlus
Key findings / conclusions: Strong association between increased BMI and surgery risk

Questions and Comments
No questions were raised.

Decision: ✅ Endorsed (Slide-sourced)

 ---

Impact of Wegovy on household shopping, lifestyle and behavioural metrics in US; Impact of Wegovy on food noise and mental wellbeing in US

Presenter(s): TMYU
Source: Transcript-sourced

Who / What / Actions

WhoWhatActionsTMYUPresented consumer behavior data related to WegovyClarify if this is market researchAllReview / decisionPending clarification

Abstract / Manuscript
Target congress / journal: Obesity Week 2025
Submission date / deadline: July 2025

Presentation Summary
Aim / Objective: Assess impact of Wegovy on consumer behavior
Design / Data sources: Data from Numerator, a tech company
Key findings / conclusions: Pending further clarification

Questions and Comments
[B] expressed concerns regarding scientific value and market research status.
[A] emphasized adherence to publication requirements.

Decision: ❌ Not endorsed (pending further clarification)

 ---

Real world cardiovascular and gastro-intestinal benefit of Wegovy compared to Zepbound in US

Presenter(s): TMYU
Source: Transcript-sourced

Who / What / Actions

WhoWhatActionsTMYUPresented comparison of Wegovy and ZepboundConduct feasibility assessmentAllReview / decisionPending data analysis

Abstract / Manuscript
Target congress / journal: Obesity Week 2025
Submission date / deadline: July 2025

Presentation Summary
Aim / Objective: Compare cardiovascular and gastrointestinal benefits
Design / Data sources: AMR PPlus database
Key findings / conclusions: Pending further data analysis

Questions and Comments
[E] questioned the additional value of the CV analysis.
[A] highlighted the risk if data is not favorable.

Decision: ⚠️ Deferred (pending data analysis)

 ---

Any Other Business





No updates.

 ---

Next Steps





Task: Clarify market research status of Wegovy proposals — Responsible: TMYU — Due: Next meeting

Compliance note:
All proposals reviewed per scientific/clinical need in line with GPP 2022 and Novo Nordisk publication policy. Commercial interest was not a deciding factor.